Recent advances in the development of multi-kinase inhibitors

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Protein kinases are crucial targets in cancer therapy, with numerous selective inhibitors developed.
• Tumorigenesis is a multifactorial process involving various signaling pathways, necessitating broader therapeutic strategies.
• Current approaches include using multiple selective kinase inhibitors or single multi-kinase inhibitors.

Purpose of the Study:

• To review the benefits and obstacles of using combinations of selective kinase inhibitors versus multi-kinase inhibitors.
• To provide an overview of recently approved and emerging multi-kinase inhibitors in cancer therapy.

Main Methods:

• Literature review of scientific publications and drug development data.
• Analysis of therapeutic strategies involving kinase inhibitors for cancer treatment.
• Comparative assessment of single-agent multi-kinase inhibition versus combination therapy.

Main Results:

• Both combination therapy and multi-kinase inhibitors offer strategies to target complex cancer signaling pathways.
• Multi-kinase inhibitors present a single-agent approach to simultaneously inhibit multiple kinases involved in tumor growth.
• The review details approved and upcoming multi-kinase inhibitors, highlighting their therapeutic potential.

Conclusions:

• Targeting multiple kinases is a rational approach for cancer therapy due to the multifactorial nature of tumorigenesis.
• Both combination therapy and multi-kinase inhibitors have distinct advantages and disadvantages that need careful consideration.
• Multi-kinase inhibitors represent a significant advancement in anticancer drug development, offering a streamlined therapeutic option.